Follow us on Twitter
twitter icon@FreshPatents


Codon patents

      

This page is updated frequently with new Codon-related patent applications.




 Chimeric nucleic acid molecules with non-aug translation initiation sequences and uses thereof patent thumbnailnew patent Chimeric nucleic acid molecules with non-aug translation initiation sequences and uses thereof
The present disclosure relates to nucleic acid vaccine compositions and methods for preventing or treating pathological conditions, such as cancer or infectious disease. Further, the disclosure provides methods for more efficient production of antigens via mrna containing one or more non-conventional start codons to promote multiplex initiation of translation in eukaryotic cells..
Tapimmune Inc.


 Design of mrna sequences to control co-translational folding of proteins patent thumbnailnew patent Design of mrna sequences to control co-translational folding of proteins
This invention relates to optimized heterologous production of properly folded and functional proteins. The present invention provides systems and methods involving determination of the optimal mrna sequence, based on the underlying rates at which codons are translated and folding kinetic of nascent-protein, that maximizes co-translational protein folding of domains in order to maximize the proper folding and quality of the protein produced.
The Penn State Research Foundation


 Formulations of nonopioid and confined opioid analgesics patent thumbnailnew patent Formulations of nonopioid and confined opioid analgesics
The preferred exemplary embodiments in the present application provide formulations and methods for the delivery of drugs, particularly drugs of abuse, having an abuse-relevant drug substantially confined in the core and a non-abuse relevant drug in a non-core region. These formulations have reduced potential for abuse.
Abbvie Inc.


 Compositions and methods for making selenocysteine containing polypeptides patent thumbnailCompositions and methods for making selenocysteine containing polypeptides
Non-naturally occurring trnasec and methods of using them for recombinant expression of proteins engineered to include one or more selenocysteine residues are disclosed. The non-naturally occurring trnasec can be used for recombinant manufacture of selenocysteine containing polypeptides encoded by mrna without the requirement of an secis element.
Yale University


 Methods for efficient, expansive, user-defined dna mutagenesis patent thumbnailMethods for efficient, expansive, user-defined dna mutagenesis
The presently disclosed subject matter provides methods for the creation of one or more user-defined mutations that can be located anywhere in a target sequence, such as in a gene. These mutations can comprise single mutations, multiple mutations, or a comprehensive codon mutagenesis library, in which all possible single codon substitutions in a gene are created.
The Johns Hopkins University


 Heterologous expression of fungal cellobiohydrolase 2 genes in yeast patent thumbnailHeterologous expression of fungal cellobiohydrolase 2 genes in yeast
The present invention provides for heterologous expression of polypeptides encoded by wild-type and codon-optimized cbh2 genes from the organisms cochliobolus heterostrophus, gibberella zeae, irpex lacteus, volvariella volvacea, and piromyces sp. In host cells, such as the yeast saccharomyces cerevisiae.
Stellenbosch University


 Ptd-smad7 therapeutics patent thumbnailPtd-smad7 therapeutics
The present technology provides methods and compositions for the treatment of inflammatory and/or tissue damage conditions. In particular, the use of smad7 compositions delivered locally or systemically to a site of inflammation and/or tissue damage is described.
The Regents Of The University Of Colorado, A Body Corporate


 Adeno-associated virus vectors for treatment of glycogen storage disease patent thumbnailAdeno-associated virus vectors for treatment of glycogen storage disease
The present disclosure describes improved adeno-associated virus (aav) vectors for gene therapy applications in the treatment of glycogen storage disease, particularly glycogen storage disease type ia (gsd-ia). Described are recombinant nucleic acid molecules, vectors and recombinant aav that include a g6pc promoter/enhancer, a synthetic intron, a g6pc coding sequence (such as a wild-type or codon-optimized g6pc coding sequence), and stuffer nucleic acid sequence situated between the g6pc promoter/enhancer and the intron, as well as between the intron and the g6pc coding sequence.
University Of Florida Research Foundation, Incorporated


 Method of increasing biomass and lipid content in a micro-organism and a genetically modified micro-organism exhibiting enhanced autophagy patent thumbnailMethod of increasing biomass and lipid content in a micro-organism and a genetically modified micro-organism exhibiting enhanced autophagy
According to an embodiment of the invention, there is provided a method of increasing biomass and lipid content in a micro-organism comprising cloning in a vector an exogenous gene sequence selected from the group comprising atg1 gene, atg6 gene, and atg8 gene sequence wherein the sequence is codon optimized for said micro-organism, for inducing autophagy; introducing the vector containing the gene into the genome of the micro-organism to yield a genetically modified micro-organism; and growing the genetically modified micro-organism in suitable medium. According to another embodiment of the invention there is provided a method of increasing biomass and lipid content in a micro-organism exposed to stress, comprising treating the microorganism with an autophagy inducing agent..
Reliance Industries Limited


 Method for producing polyunsaturated fatty acids patent thumbnailMethod for producing polyunsaturated fatty acids
The invention relates to a method for producing eicosapentanoic acid, docosapentanoic acid and/or docohexanoic acid in transgenic plants. According to said method, the plant is provided with at least one nucleic acid sequence coding for a polypetide with a Δ6 desaturase activity, at least one nucleic acid sequence coding for a polypeptide with a Δ6 elongase activity, at least one nucleic acid sequence coding for a polypeptide with a Δ5 desaturase activity, and at least one nucleic acid sequence coding for a polypeptide with a Δ5 elongase activity, the nucleic acid sequence coding for a polypeptide with a Δ5 elongase activity being modified in relation to the nucleic acid sequence in the organism from which the sequence originates, such that it is adapted to the codon use in at least one type of plant.
Basf Plant Science Gmbh


Chimeric nucleic acid molecules with non-aug translation initiation sequences and uses thereof

The present disclosure relates to nucleic acid vaccine compositions and methods for preventing or treating pathological conditions, such as cancer or infectious disease. Further, the disclosure provides methods for more efficient production of antigens via mrna containing one or more non-conventional start codons to promote multiplex initiation of translation in eukaryotic cells..
Tapimmune Inc.

Effect of ppegid1c on vegetative growth of fruit trees

The genetic basis for a recessive dwarf trait (dw) in peach (prunus persica) was determined. Using a sequencing-based bulk-segregant mapping strategy, dw was positioned on the distal end of peach chromosome 6.
The United States Of America, As Represented By The Secretary Of Agriculture

Live-attenuated virus and methods of production and use

Presented herein are live-attenuated viruses and methods of generating thereof from a parental virus through a plurality of nucleotide substitutions in the viral genome. The nucleotide substitutions result in a change in codon usage bias within codons of one or more protein encoding sequences and no change in amino acid sequences of the proteins.
The University Of Hong Kong

Chimeric nucleic acid molecules with non-aug translation initiation sequences and uses thereof

The present disclosure relates to nucleic acid vaccine compositions and methods for preventing or treating pathological conditions, such as cancer or infectious disease. Further, the disclosure provides methods for more efficient production of antigens via mrna containing one or more non-conventional start codons to promote multiplex initiation of translation in eukaryotic cells..
Tapimmune Inc.

Treating pain in patients with hepatic impairment

An extended release composition for an analgesic active pharmaceutical ingredient which may be an opioid, preferably hydrocodone as the only active ingredient. The extended release composition preferably comprises a extended release composition which may be in the form of beads contained in an oral dosage form such as gelatin capsules.
Pernix Ireland Pain Limited

Sin nombre virus full-length m segment-based dna vaccines

The invention contemplates a new synthetic, codon-optimized sin nombre virus (snv) full-length m gene open reading frame (orf) that encodes a unique consensus amino acid sequence. The snv orf was cloned into a plasmid to form the first stable recombinant snv full-length m gene that elicits neutralizing antibodies.
The United States Of America, As Rep. By The Sec'y Of The Army, For U.s. Army Medical Research Insti

Pharmaceutical compositions for treating or preventing pain

Methods and compositions are provided which comprise effective amounts of one or more analgesics, such as hydrocodone or acetaminophen, and an antiemetic, such as promethazine, to treat or prevent pain in a subject, and to reduce or prevent an adverse effect associated with the analgesics.. .
Locl Pharma, Inc.

Methods and compositions for determining virus susceptibility to integrase inhibitors

Methods and compositions for the efficient and accurate determination of hiv susceptibility to an integrase inhibitor and/or hiv replication capacity are provided. In certain aspects, the methods involve detecting in a biological sample a nucleic acid encoding an hiv integrase that comprises a primary mutation at codon 143, wherein the mutation at codon 143 does not encode arginine (r) or cysteine (c), and wherein the presence of the integrase-encoding nucleic acid in the biological sample indicates that the hiv has a decreased susceptibility to an integrase inhibitor or altered replication capacity relative to a reference hiv.
Laboratory Corporation Of America Holdings

Histidine engineered light chain antibodies and genetically modified non-human animals for generating same

A genetically modified non-human animal is provided, wherein the non-human animal expresses an antibody repertoire capable of ph dependent binding to antigens upon immunization. A genetically modified non-human animal is provided that expresses a single light chain variable domain derived from a single rearranged light chain variable region gene in the germline of the non-human animal, wherein the single rearranged light chain variable region gene comprises a substitution of at least one non-histidine encoding codon with a histidine encoding codon.
Regeneron Pharmaceuticals, Inc.

Method for detection of a nucleic acid target sequence

Disclosed is a method of facilitating detection of a nucleic acid target sequence. The method may include obtaining a toehold-mediated dna strand displacement apparatus comprising a portion complementary to the nucleic acid target sequence.
Totemid Inc.

Synthetic genes

The invention provides synthetic nucleic acid sequences encoding proteins of interest that are particularly adapted to express well in plants. The claimed synthetic sequences utilize plant-optimized codons roughly in the same frequency at which they are utilized, on average, in genes naturally occurring in the plant species.
Dow Agrosciences Llc

Codon-optimized gene for mutated shrimp luciferase and use thereof

There has been a demand for a codon-optimized gene for the mutated catalytic domain of oplophorus luciferase, which is capable of efficiently expressing a protein both in a cultured animal cell and escherichia coli. There has also been a demand for a substrate coelenterazine analogue showing a higher activity than that of native 19 kda protein.
Jnc Corporation

Production charged non-protein amino acid-containing peptide

The present invention provides a method of producing a peptide containing a charged non-proteinogenic amino acid. It includes a step of expressing a peptide in a cell-free translation system including (i) at least one trna to which a non-proteinogenic amino acid having a protecting-group-introduced charged group has been bound and (ii) a nucleic acid that encodes the peptide and contains at least one codon corresponding to an anticodon of the trna; and a step of removing the protecting group of the non-proteinogenic amino acid residue contained in the peptide..

Sustained release monoeximic formulations of opioid and nonopioid analgesics

The present invention relates to monoeximic solid dosage forms for administering pharmaceutical agents, particularly hydrocodone and acetaminophen, methods for preparing said dosage forms, and methods for providing therapeutic agents to patients in need of treatment.. .
Abbvie Inc.

Poxvirus expression system

There is provided a method for inserting a nucleic acid sequence that encodes a foreign peptide into a poxvirus genome, said method comprising: identifying in the poxvirus genome a poxvirus open reading frame wherein said open reading frame is characterised by an initial atg start codon and wherein expression of said open reading frame is driven by an operably-linked poxvirus promoter located upstream of the open reading frame and wherein expression of said open reading frame provides a peptide that is non-essential to viability of the poxvirus; and inserting the nucleic acid sequence that encodes the foreign peptide at a position downstream of the poxvirus promoter; wherein following said insertion, (i) the nucleic acid that encodes the foreign peptide is operably-linked to the poxvirus promoter and expression of said nucleic acid is driven by said poxvirus promoter; and (ii) translation of the foreign peptide is initiated at an atg start codon located at the same position as the atg start codon of the poxvirus open reading frame. Also provided are a poxvirus vector and corresponding uses of the poxvirus vector in medicine..
Isis Innovation Limited

Computationally optimized broadly reactive antigens for h5n1 and h1n1 influenza viruses

Described herein is the generation of optimized h5n1 and h1n1 influenza ha polypeptides for eliciting a broadly reactive immune response to influenza virus isolates. The optimized ha polypeptides were developed through a series of ha protein alignments, and subsequent generation of consensus sequences, based on h5n1 and h1n1 influenza isolates.
University Of Pittsburgh - Of The Commonwealth System Of Higher Education

Method for producing peptide library, peptide library, and screening method

An object of the present invention is to provide a method for producing a peptide library capable of incorporating an arbitrary number of arbitrary proteinogenic and/or non-proteinogenic amino acids in an arbitrary site. The invention provides a method for producing a peptide library including 1×106 or more kinds of peptides containing amino acids encoded by n1n2n3, including a step of preparing an mrna library including mrnas which encode peptides of the peptide library and each contain at least one n1n2n3; and a step of translating each mrna of the mrna library in a cell-free translation system added with trna containing an anticodon to any one of n1n2n3 codons and charged with an amino acid corresponding to the codon (wherein, n1, n2, and n3 are each independently selected from adenine (a), guanine (g), cytosine (c), and uracil (u) and an arbitrary amino acid is reassigned to each n1n2n3)..
Peptidream Inc.

Herbal composition and use

The present invention provides herbal compositions comprise radix dioscoreae, radix codonopsis, and radix astragalus membranaceus. The herbal compositions are used to suppress intestinal glucose uptake of intestinal villus and decrease blood glucose levels.

Process for preparing oxycodone compositions

In certain embodiments the invention is directed to a process for preparing an oxycodone hydrochloride composition having less than 25 ppm of 14-hydroxycodeinone.. .
Rhodes Technologies

Treating pain in patients with hepatic impairment

An extended release composition for an analgesic active pharmaceutical ingredient which may be an opioid, preferably hydrocodone as the only active ingredient. The extended release composition preferably comprises a extended release composition which may be in the form of beads contained in an oral dosage form such as gelatin capsules.
Pernix Ireland Pain Limited

Method and device for optimizing a nucelotide sequence for the purpose of expression in a protein

The invention relates to a method for optimizing a nucleotide sequence for expression of a protein on the basis of the amino acid sequence of the protein, in which for a particular region there is specification of a test sequence with m optimization positions on which the codon occupation is varied, a quality function being used to ascertain the optimal codon occupation on these optimization positions, and one or more codons of this optimal occupation being specified as codons of the optimized nucleotide sequence. These steps are iterated, with the codons of the optimized nucleotide sequence which are specified in the preceding steps remaining unchanged in subsequent iteration steps.
Thermo Fisher Scientific Geneart Gmbh

Peptide inhibitor of hiv reverse transcription

Disclosed are peptides that exhibit good binding to the anticodon stem and loop (asl) of human lysine trna species, trnalys3. Using a search algorithm combining monte carlo (mc) and self-consistent mean field (scmf) techniques, the peptides were evolved a with the ultimate purpose of using them to break the replication cycle of hiv-1 virus.
The Research Foundation For The State University Of New York

Treating pain in patients with hepatic impairment

An extended release composition for an analgesic active pharmaceutical ingredient which may be an opioid, preferably hydrocodone as the only active ingredient. The extended release composition preferably comprises a extended release composition which may be in the form of beads contained in an oral dosage form such as gelatin capsules.
Pernix Ireland Pain Limited

Oral dosage forms for oxygen-containing active agents and oxyl-containing polymer

The disclosed invention is drawn to pharmaceutical tablets that provide delivery of active agents having at least three oxygen-containing groups, a tri-oxy active agent, as well as a second active ingredient. Non-limiting examples of three oxygen-containing group active agents include guaifenesin, codeine, hydrocodone, and their pharmaceutically acceptable salts.
Spriaso Llc

Process for preparing oxycodone compositions

In certain embodiments the invention is directed to a process for preparing an oxycodone hydrochloride composition having less than 25 ppm of 14-hydroxycodeinone.. .
Rhodes Technologies

Process for preparing oxycodone compositions

In certain embodiments the invention is directed to a process for preparing an oxycodone hydrochloride composition having less than 25 ppm of 14-hydroxycodeinone.. .
Rhodes Technologies

Process for preparing oxycodone compositions

In certain embodiments the invention is directed to a process for preparing an oxycodone hydrochloride composition having less than 25 ppm of 14-hydroxycodeinone.. .
Rhodes Technologies



Codon topics:
  • Hydrocodone
  • Nucleic Acid
  • Acetaminophen
  • Carboxylic Acid
  • Benzoic Acid
  • Genetically
  • Recombinant
  • Amino Acid
  • Nucleotide
  • Reverse Transcriptase Inhibitors
  • Reverse Transcriptase Inhibitor
  • Reverse Transcriptase
  • Antibodies
  • Base Sequence
  • Replication


  • Follow us on Twitter
    twitter icon@FreshPatents

    ###

    This listing is a sample listing of patent applications related to Codon for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Codon with additional patents listed. Browse our RSS directory or Search for other possible listings.


    4.4411

    file didn't exist2295

    478893 - 0 - 54